Nilotinib hydrochloride sesquihydrate is a stable, hydrated salt form of nilotinib used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). As a tyrosine kinase inhibitor, it blocks the BCR-ABL protein to stop cancer cell growth. The sesquihydrate form offers benefits in drug formulation, including improved stability and consistent performance. It is grouped under the following drug class(es): Antineoplastic agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride and hydrate (2:2:3). Its PubChem CID is 155929024.
Nilotinib hydrochloride sesquihydrate
| CAS No | 2727104-79-0 |
|---|---|
| Molecular Formula | C56H52Cl2F6N14O5 |
| Molecular Weight | 1186.0 g/mol |
| Synonyms | 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;trihydrate;dihydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nilotinib hydrochloride sesquihydrate is a stable, hydrated salt form of nilotinib used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
The listed CAS number is 2727104-79-0.
The listed molecular formula is C56H52Cl2F6N14O5.
The listed molecular weight is 1186.0 g/mol.
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;trihydrate;dihydrochloride.
The source lists benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride and hydrate (2:2:3).